ICON plc downgraded by Goldman with a new price target
$ICLR
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Goldman downgraded ICON plc from Buy to Neutral and set a new price target of $200.00 from $250.00 previously
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/29/2025 | $150.00 | Overweight → Neutral | Analyst |
| 4/14/2025 | $157.00 | Buy → Hold | TD Cowen |
| 4/10/2025 | $165.00 | Overweight → Equal Weight | Barclays |
| 3/21/2025 | $250.00 → $200.00 | Buy → Neutral | Goldman |
| 1/7/2025 | $263.00 | Outperform | RBC Capital Mkts |
| 10/24/2024 | $340.00 | Outperform → Neutral | Robert W. Baird |
| 10/14/2024 | Neutral | Redburn Atlantic | |
| 9/18/2024 | $379.00 | Outperform | Leerink Partners |
ICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that it will release its financial results for the second quarter 2025 after the market closes on Wednesday, July 23, 2025. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, July 24, 2025 at 8:00am ET. Any changes to this event and links to the live webcast will be posted on the Investor section of our website under "Events". A webcast replay of the conference call will be available approximately one hour following the conclusion of the call. About ICON plc ICON plc is a world-leading clinical researc
ICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the William Blair 45th Annual Growth Stock Conference on Wednesday, June 4, 2025 at 10.40 am CT. Any changes to this event and links to the live webcast (where available) will be posted on the Investor section of our website under "Events". About ICON plc ICON plc is a world-leading clinical research organisation powered by healthcare intelligence. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public he
ICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today releases its ICON Cares 2024 Report. The report outlines how the company is delivering on its environmental, social and governance (ESG) goals, as delivered through its ICON Cares program. In recognition of its efforts in 2024, ICON received a score of 72/100 from EcoVadis, a leading provider of business sustainability ratings, an increase of two points on the previous score, earning ICON a silver medal. ICON also achieved a B- score on its CDP Climate Change response. Most recently, ICON has been named by TIME magazine as one the World's Best Companies in Sustainable Growth 202
6-K - ICON PLC (0001060955) (Filer)
6-K - ICON PLC (0001060955) (Filer)
6-K - ICON PLC (0001060955) (Filer)
Analyst downgraded ICON plc from Overweight to Neutral and set a new price target of $150.00
TD Cowen downgraded ICON plc from Buy to Hold and set a new price target of $157.00
Barclays downgraded ICON plc from Overweight to Equal Weight and set a new price target of $165.00
MELBOURNE, Australia and INDIANAPOLIS, April 04, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April 20251. Ms. Whitaker is a seasoned healthcare leader and advisor with over 30 years' global corporate experience spanning large pharmaceutical, biotech and speciality pharmaceutical companies, including clinical research and manufacturing organizations. She has held Board positions on a range of Nasdaq-listed clinical and commercial stage life sciences companies. Ms. Whitaker is currently serving as a NED at Icon PLC
ICON plc (NASDAQ:ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced the appointment of Barry Balfe as Chief Operating Officer (COO). Barry is a long-tenured ICON employee with over 20 years of service and brings extensive leadership experience and capability to the role of COO. He has held a number of leadership roles across both full service and functional solutions at ICON and has very successfully supported the growth of new and existing customer partnerships. His strong focus and track record on operational excellence, quality & delivery will enable the company to deliver greater value to our customers and further enhance our strategy to
ICON plc (NASDAQ:ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced the appointment of Nigel Clerkin as its new Chief Financial Officer (CFO). Nigel brings extensive experience and capability to the role of CFO. He commenced his career with KPMG, before joining Elan Corporation where he held a number of roles of increasing responsibility over a fifteen-year career, culminating in the role of group CFO in 2011, which he held until 2014. Nigel then moved to be CFO at ConvaTec, a global medical and technologies company, before becoming UDG Healthcare's CFO in 2018. During his tenure with UDG, he led substantial change and improvement programmes
ICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that it will release its financial results for the second quarter 2025 after the market closes on Wednesday, July 23, 2025. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, July 24, 2025 at 8:00am ET. Any changes to this event and links to the live webcast will be posted on the Investor section of our website under "Events". A webcast replay of the conference call will be available approximately one hour following the conclusion of the call. About ICON plc ICON plc is a world-leading clinical researc
Highlights Net business wins in the quarter of $2,022 million; a net book to bill in the quarter of 1.01. Closing backlog of $24.7 billion, an increase of 0.3% on quarter four 2024 and 6.0% on quarter one 2024. Quarter one revenue was $2,001.3 million and quarter one adjusted EBITDA was $390.7 million or 19.5% of revenue. GAAP net income for the quarter was $154.2 million or $1.90 per diluted share. Quarter one adjusted net income was $258.3 million or $3.19 per diluted share. Net debt was $2.9 billion at March 31, 2025 with a net debt to adjusted EBITDA ratio of 1.7x. $250.0 million worth of stock repurchased in quarter one at an average price of $184. Updating full-year 20
ICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that it will release its financial results for the first quarter 2025 after the market closes on Wednesday, April 30, 2025. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, May 1, 2025 at 8:00am ET. Any changes to these events and links to the live webcasts (where available) will be posted on the Investor section of our website under "Events". A webcast replay of the conference call will be available approximately one hour following the conclusion of the call. About ICON plc ICON plc is a world-leading
SC 13G/A - ICON PLC (0001060955) (Subject)
SC 13G/A - ICON PLC (0001060955) (Subject)
SC 13G/A - ICON PLC (0001060955) (Subject)